Difference in admissions with mCRPC treatments

New research published in conjunction with the 2017 ASCO Annual Meeting has observed significant increases in multiple hospital admission (HA) incidence rate ratios (IRRs) post- versus pre-abiraterone (ABI) treatment, and these IRRs were significantly lower for enzalutamide (ENZA) versus ABI-treated patients for multiple HAs. ENZA and ABI are approved to treat metastatic castration-resistant prostate cancer (mCRPC) in chemotherapy-naïve patients, but few real-world analyses exist to compare HA pre- and post-treatment. In this study (J Clin Oncol 35, 2017 [suppl; abstr e16524]), patients aged 18 years or older who initiated ENZA or ABI (two cohorts) from January 2014 to December 2015…